Fig. 2.
Effects of anti-CD19-Fab-SEAm against 2 CD19+ lymphoma cell line targets. T-cell targeting to (A) Raji cells (CD19+HLA-DR++) and (B) RJ225 cells (CD19+HLA-DRlow) mediated by anti-CD19-Fab-SEAm fusion protein, native SEA, or C215-Fab-SEAm control fusion protein. Each value is the mean of triplicate samples. The E:T ratio was 40:1, and specific cytotoxicity was measured in a 51Cr-release assay.